Literature DB >> 9833988

Biotransformation of estradiol in the human keratinocyte cell line HaCaT: metabolism kinetics and the inhibitory effect of ethanol.

R Altenburger1, T Kissel.   

Abstract

PURPOSE: The aim of our study was to investigate the kinetics of beta-estradiol (E2) metabolism in the human keratinocyte cell line HaCaT and to estimate the effect of the potential inhibitor ethanol on the biotransformation reaction.
METHODS: The formation rates of estrone (E1) in dependence on substrate concentrations were determined in HaCaT cells using tritium labelled E2. Experiments were conducted with and without addition of dehydroepiandrosterone (DHEA) and ethanol. Possible toxic effects on the cells due to ethanol were investigated by cytotoxicity tests.
RESULTS: The metabolism of E2 in HaCaT cells exhibited Michaelis-Menten kinetics with Km and Vmax values of 3.5 microM and 216 pmol x mg(-1) protein x h(-1), respectively. The reaction was inhibited by DHEA and ethanol. The alcohol showed a reversible competitive inhibition mechanism for concentrations of 4 to 8% (v/v). Lower ethanol concentrations had no effect, whereas levels > or =10% significantly decreased cell viability leading to a different inhibition mechanism.
CONCLUSIONS: The HaCaT cell line seems to be a suitable model for studying enzyme kinetics equivalent to the human skin. The concentration dependent inhibitory effect of ethanol observed in this cell line may be relevant for the transdermal E2 application in patients.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9833988     DOI: 10.1023/a:1011996226112

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  21 in total

Review 1.  Cutaneous metabolism of xenobiotics.

Authors:  J Kao; M P Carver
Journal:  Drug Metab Rev       Date:  1990       Impact factor: 4.518

2.  Skin structure and metabolism: relevance to the design of cutaneous therapeutics.

Authors:  D A Bucks
Journal:  Pharm Res       Date:  1984-07       Impact factor: 4.200

3.  In vitro interconversion of estrone and 17-beta-estradiol in human skin and vaginal mucosa.

Authors:  G D Weinstein; P Frost; S L Hsia
Journal:  J Invest Dermatol       Date:  1968-07       Impact factor: 8.551

4.  Skin absorption and cutaneous first pass metabolism of topical steroids: in vitro studies with mouse skin in organ culture.

Authors:  J Kao; J Hall
Journal:  J Pharmacol Exp Ther       Date:  1987-05       Impact factor: 4.030

5.  Epidermal keratinocytes: a source of 5 alpha-dihydrotestosterone production in human skin.

Authors:  L Milewich; V Kaimal; C B Shaw
Journal:  J Clin Endocrinol Metab       Date:  1986-04       Impact factor: 5.958

6.  Activity of 17 beta-hydroxysteroid oxidoreductase in tissues of the human fetus.

Authors:  L Milewich; P C MacDonald; B R Carr
Journal:  J Endocrinol       Date:  1989-12       Impact factor: 4.286

7.  Rate control in transdermal beta-estradiol reservoir membrane systems: the role of membrane and adhesive layer.

Authors:  R Altenburger; U D Rohr; T Kissel
Journal:  Pharm Res       Date:  1998-08       Impact factor: 4.200

8.  Inhibition of 17 beta-hydroxysteroid dehydrogenase activity in human endometrium by adrenal androgens.

Authors:  R C Bonney; M J Reed; V H James
Journal:  J Steroid Biochem       Date:  1983-01       Impact factor: 4.292

9.  Plasma levels of dehydroepiandrosterone and 17 beta-estradiol after intramuscular administration of Gynodian-Depot in 3 women.

Authors:  B Düsterberg; H Wendt
Journal:  Horm Res       Date:  1983

10.  Maintenance of skin viability during in vitro percutaneous absorption/metabolism studies.

Authors:  S W Collier; N M Sheikh; A Sakr; J L Lichtin; R F Stewart; R L Bronaugh
Journal:  Toxicol Appl Pharmacol       Date:  1989-07       Impact factor: 4.219

View more
  1 in total

1.  The human keratinocyte cell line HaCaT: an in vitro cell culture model for keratinocyte testosterone metabolism.

Authors:  R Altenburger; T Kissel
Journal:  Pharm Res       Date:  1999-05       Impact factor: 4.200

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.